$18 million in U.S. defense funding to develop skin substitute Print E-mail
By Staff and Wire Reports   
Friday, 12 November 2010 09:31

The Associated Press has just published a story which states that Switzerland based Lonza Group Ltd. is announcing more than $18 million in U.S. defense funding to develop their skin substitute grown from the patient's own cells.

Spokeswoman Melanie Disa said Thursday that Lonza's Walkersville unit received a $1.5 million grant and a $16.9 million contract to develop and commercialize its PermaDerm product.

As our readers know, we have been following this developing story and Permaderm was recently licensed worldwide marketing rights to Regenicin, Inc. (OTC:RGIN) and the company is playing a critical role in the development and commercialization of the therapeutic candidate.

Bloomberg: Firm in Md. gets defense deal for skin substitute

This morning, Regenicin, issued a press release stating that company CEO, Randall McCoy will be presenting this morning at the 1st Annual LifeTech Investor Conference at the JW Marriott Marquis today in Miami.

Mr. McCoy will present Regenicin's core concept and business model for bringing regenerative medicine products to market.  Regenicin will be among twenty four public biotechnology and medical technology companies that will be presenting to institutional and private investors.

In addition to Regenicin, the conference will feature the University of Miami Miller School of Medicine Technology Showcase as well as panels of experts from their renowned centers such as the Sylvester Cancer Center, the Bascom Palmer Eye Institute and the Stem Cell Institute.

Investors interested in more information on the event can register at: http://www.LifeTechCapital.com/conference.

Disa says clinical trials should begin in early 2011 at Fort Sam Houston, Texas, and another site yet to be determined.

We previously reported that clinical data from over 150 child burn patients has already been submitted to the FDA as part of an effort to get fast humanitarian approval for the technology. Company officials have not commented.


"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus